Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) EBITDA (2020 - 2024)

SELLAS Life Sciences (SLS) has disclosed EBITDA for 8 consecutive years, with -$6.9 million as the latest value for Q4 2024.

  • On a quarterly basis, EBITDA rose 15.4% to -$6.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$31.5 million, a 16.78% increase, with the full-year FY2024 number at -$31.5 million, up 16.78% from a year prior.
  • EBITDA was -$6.9 million for Q4 2024 at SELLAS Life Sciences, up from -$7.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.2 million in Q1 2021 to a low of -$16.7 million in Q1 2022.
  • A 5-year average of -$7.7 million and a median of -$7.5 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 44.76% in 2021, then crashed 645.43% in 2022.
  • SELLAS Life Sciences' EBITDA stood at -$4.2 million in 2020, then plummeted by 179.37% to -$11.6 million in 2021, then grew by 18.7% to -$9.4 million in 2022, then rose by 13.43% to -$8.2 million in 2023, then increased by 15.4% to -$6.9 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's EBITDA are -$6.9 million (Q4 2024), -$7.3 million (Q3 2024), and -$7.6 million (Q2 2024).